Psychiatric News reports a study found that “adults ages 65 and older with tardive dyskinesia (TD) given valbenazine for up to 48 weeks experienced substantial and sustained improvements in symptoms while maintaining psychiatric stability.” Researchers observed that “40% of older participants experienced a meaningful response to valbenazine (≥50% improvement in AIMS) at eight weeks, which rose to 65% at 24 weeks and 82% at 48 weeks; the improvements in older adults were comparable to those seen in younger participants.” Researchers concluded, “This article reports on data indicating that once-daily valbenazine is effective and well-tolerated in the ≥65-year age group.” The study was published in the Journal of Clinical Psychiatry.
Related Links:
— “Valbenazine Significantly Improves Tardive Dyskinesia in Older Adults Over Long-Term,” Psychiatric News, April 30, 2025